Updated:
Gemseki
Gemseki is based in Oakland; the profile covers headquarters, registration, AUM band and key contacts for private-markets fundraising.
Overview
株式会社新日本科学Gemseki事業部は、創薬シーズ・技術の導出・導入の仲介をグローバルに行う、創薬支援の事業部です。
General information
Location
Region
North America
Country
United States
City
Oakland
Corporate office
Oakland, Palo Alto, Seoul, Montreal, Tel Aviv (per firm website)
Additional offices
Palo Alto, CA · Seoul, South Korea · Montreal, Canada · Tel Aviv, Israel
Sector focus
Frequently asked questions
Who runs investment decisions at Gemseki?
Gemseki does not publicly name an investment committee or managing partner. It operates as a business unit of Shin Nippon Biomedical Laboratories, with no disclosed investment fund or deployment vehicle.
How does Gemseki source proprietary deal flow?
The firm relies on its 薬市楽座 platform, which aggregates drug seeds and technologies from academic labs, biotech companies, and research institutes across its multi-office network spanning North America, East Asia, and Israel.
What investment stages does Gemseki typically target?
Gemseki's listings center on discovery and preclinical-stage drug candidates and research technologies. It does not publish a formal stage mandate, but the language 'drug seeds' signals an emphasis on early, pre-clinical assets.
How is Gemseki related to Shin Nippon Biomedical Laboratories?
Gemseki is a dedicated business unit of SNBL, a publicly listed Japanese pharmaceutical services and contract research organization. The unit functions as a global licensing intermediary under the parent company's corporate umbrella.
Profile maintained by Altss. Updated: . To correct this record or make a privacy request, send the page URL and your evidence to privacy@altss.com; corrections are free.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: